BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32473508)

  • 1. A novel phytochemical from Dipteris wallichii inhibits human β-secretase 1: Implications for the treatment of Alzheimer's disease.
    Chetia P; Mazumder MK; Mahanta S; De B; Dutta Choudhury M
    Med Hypotheses; 2020 Oct; 143():109839. PubMed ID: 32473508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer's Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition.
    Das S; Sengupta S; Chakraborty S
    ACS Chem Neurosci; 2020 Nov; 11(21):3510-3522. PubMed ID: 33073981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design.
    Ugbaja SC; Lawal IA; Kumalo HM; Lawal MM
    Curr Drug Targets; 2022; 23(3):266-285. PubMed ID: 34370634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE1: A Key Regulator in Alzheimer's Disease Progression and Current Development of its Inhibitors.
    Patel S; Bansoad AV; Singh R; Khatik GL
    Curr Neuropharmacol; 2022; 20(6):1174-1193. PubMed ID: 34852746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential lead compounds against BACE1 through in-silico screening of phytochemicals of Medhya rasayana plants for Alzheimer's disease management.
    Nadh AG; Revikumar A; Sudhakaran PR; Nair AS
    Comput Biol Med; 2022 Jun; 145():105422. PubMed ID: 35354103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baicalein as a Potential Inhibitor against BACE1 and AChE: Mechanistic Comprehension through In Vitro and Computational Approaches.
    Han J; Ji Y; Youn K; Lim G; Lee J; Kim DH; Jun M
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31703329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.
    Chiocco MJ; Kulnane LS; Younkin L; Younkin S; Evin G; Lamb BT
    J Biol Chem; 2004 Dec; 279(50):52535-42. PubMed ID: 15452128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor.
    Youn K; Park JH; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2016 Oct; 8(10):. PubMed ID: 27754406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
    Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
    J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
    Liang ZM; Peng YH; Chen Y; Long LL; Luo HJ; Chen YJ; Liang YL; Tian YH; Li SJ; Shi YS; Zhang XM
    Nucleic Acid Ther; 2019 Dec; 29(6):359-366. PubMed ID: 31513457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.